We use cookies to ensure that the website works as intended and to collect statistics on its use so that we can improve your web site experience.

×

Investor Relations Policy


Aker BioMarine’s investor relations (IR) policy sets the basic principles for the company’s communication and dialogue with capital markets participants. Aker BioMarine aims to serve the financial market with relevant, comprehensive and timely information about the company, to form a good basis for making decisions related to valuation and trade of the Aker BioMarine share. The company seeks to engage in an open and continuous dialogue with the financial market.

Aker BioMarine’s IR activities are conducted in compliance with prevailing rules and regulations, including the latest version of Oslo Børs’ Code of Practice for IR. 

Aker BioMarine shall ensure equal treatment of financial market participants and equal opportunities to access relevant information. The main communication channels are stock exchange releases, press releases and the company's website.

Aker BioMarine publishes financial results on a quarterly basis according to its financial calendar which is published annually on the company’s website and to the Oslo Stock Exchange.

Members of the executive management participate actively in dialogue with the financial market, while daily communication is handled by Investor Relations. The dialogue with the market takes form primarily through annual reports, quarterly reports, meetings with investors and analysts, participation in important financial industry conferences, and capital markets events organized by Aker BioMarine, and use of the company's website.

All information will be provided in English.

Aker BioMarine shall observe a silent period about three weeks prior to the publishing of quarterly financial results. Aker BioMarine does not attend any investor- or analyst meetings, or financial conferences during these periods.

 

Investor Contact

CARL CHR. BACHKE

SVP Investor Relations, Aker BioMarine ASA

+47 909 808 48

carl.bachke@akerbiomarine.com

 

 

ANNUAL REPORT 2020

IMPROVING HUMAN AND PLANETARY HEALTH

Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. Aker BioMarine’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and to customers around the world.